Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, with longer-term open
NASDAQ:DFTX